All ClpP agonists decreased cell viability in multiple breast cancer cells, including MB231 [triple-negative breast cancer (TNBC), basal B], MB453 (HER2-amplified), MCF7 (estrogen receptor positive; Fig. 1B). This evidence concerns the gene ESR1 and breast carcinoma.